BioSpace News Archive

Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases.

Evaxion Biotech A/S announces an increased focus on its strategy around its core AI capabilities allowing fast and de-risked development of its pipeline.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”) has demonstrated the utility of a human in vitro model of iPSC-derived excitatory neurons for a better understanding of which forms of amyloid beta oligomers contribute to the pathogenesis of AD in the human brain.

This award honors and confirms PharmaBlock’s commitment to green chemistry and its achievement in developing innovative solutions for sustainable development in the pharmaceutical industry.

Aadi Bioscience, Inc. today provided a corporate update and announced financial results for the fourth quarter and full-year 2022.

The Michael J. Fox Foundation for Parkinson’s Research announced the culmination of the “Ken Griffin Alpha-synuclein Imaging Competition,” a $10-million program launched in 2019 in pursuit of an imaging tracer to visualize the key protein alpha-synuclein in the living brains of people with Parkinson’s disease.

W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with 5-year follow-up (NCT05409976) to evaluate the investigational GORE® VIAFORT Vascular Stent for the Treatment of Symptomatic Inferior Vena Cava (IVC) Obstruction with or without combined Iliofemoral Obstruction.

CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, names Adel Malek, MD PhD as the company’s Chief Medical Officer.

Codagenix Inc. today announced that Kimber Poffenberger, Ph.D., has been appointed Chief Strategy Officer.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 22, 2023 , the company approved non-statutory stock options to purchase an aggregate of 58,465 shares of its common stock and 29,710 restricted stock units (“RSUs”).